A First-in-Human, Open-label, Dose-finding Trial to Evaluate the Safety and Antitumor Activity of GEN1056 in Subjects With Advanced Solid Tumors
Latest Information Update: 06 Mar 2025
At a glance
- Drugs GEN-1056 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Genmab
Most Recent Events
- 04 Mar 2025 Planned End Date changed from 18 Dec 2025 to 21 Oct 2025.
- 04 Mar 2025 Planned primary completion date changed from 18 Dec 2025 to 21 Oct 2025.
- 24 May 2024 Planned End Date changed from 31 May 2024 to 18 Dec 2025.